New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
doi 10.33978/2307-3586-2019-15-38-24-29
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Medforum

Related search

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Low-Stage High-Grade Serous Ovarian Carcinomas

International Journal of Gynecological Pathology
GynecologyForensic MedicinePathologyObstetrics
2016English

Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2016English

Proteome Profiling of Low Grade Serous Ovarian Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2019English

Targeting IDH1 as a Pro-Senescent Therapy in High-Grade Serous Ovarian Cancer

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2019English

Predictors of Long-Term Survival Among High-Grade Serous Ovarian Cancer Patients

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2019English

Integrated Analysis to Identify Molecular Biomarkers of High-Grade Serous Ovarian Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy